October 04, 2026 09:00 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Asian Games 2026: India beat Pakistan to clinch gold in men's cricket | flydubai cockpit attack: Deleted posts expose Omani co-pilot’s views on women, alleged extremist past | flydubai cockpit horror: Omani co-pilot Hamam al-Hammami attacked Captain Smit Machchhar with crash axe, tried to seize control | flydubai temporarily suspends all Israel flights after co-pilot’s alleged cockpit attack, crash attempt | Grounded in Oman over ‘radical views’, then hired by flydubai: What we know about Omani pilot Hamam al-Hammami | ‘Hanuman Chalisa gave me courage’: Smit Machchhar recounts flydubai cockpit battle to PM Modi | PM Modi speaks to Flydubai pilot Smit Machchhar who foiled crash plot, praises his courage | Putin praises Modi’s ‘good ideas’ to end Ukraine war, thanks Indian PM for peace efforts | Flydubai cockpit attack: Injured Indian pilot Smit Machchhar airlifted to Abu Dhabi | India backs brave flydubai pilot Smit Machchhar, Ambassador meets family after cockpit attack
Corona Remedies
Corona Remedies listed at 38% premium. Photo: ChatGPT

Corona Remedies storms Dalal Street! Shares list at 38% premium on debut

| @indiablooms | Dec 15, 2025, at 11:19 am

Mumbai/IBNS: Pharmaceutical firm Corona Remedies made a strong debut on the stock market on Monday, listing at a 38% premium over its IPO price on the National Stock Exchange (NSE), media reports said.

The company’s shares were listed at ₹1,470 apiece on the NSE, marking a 38.42% premium over the issue price.

On the BSE, the stock debuted at ₹1,452 per share, a 36.72% premium.

The ₹655.37-crore IPO, which was entirely an offer for sale, had a price band of ₹1,008–1,062 per share and was open for subscription from December 8 to 10.

Headquartered in Ahmedabad, Gujarat, Corona Remedies is an Indian pharmaceutical company with a strong presence in branded generics, catering to both chronic and acute therapy segments.

The robust listing underscored strong investor confidence in the company’s growth outlook and financial performance, reflecting sustained demand for quality pharma IPOs in the Indian market.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.